Cited by 370SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies ResearchCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Open access

Winkler, Emma S., Gilchuk, Pavlo, Yu, Jinsheng, Bailey, Adam L., Chen, Rita E., Chong, Zhenlu, Zost, Seth J., Jang, Hyesun, Huang, Ying, Allen, James D., Case, James Brett, Sutton, Rachel E., Carnahan, Robert H., Darling, Tamarand L., Boon, Adrianus C.M., Mack, Matthias, Head, Richard D., Ross, Ted M., Crowe, James E., Diamond, Michael S.·2021·Cell

DOI 10.1016/j.cell.2021.02.026PMC PMC7879018

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

SARS-CoV-2 has caused the global COVID-19 pandemic. Although passively delivered neutralizing antibodies against SARS-CoV-2 show promise in clinical trials, their mechanism of action in vivo is incompletely understood. Here, we define correlates of protection of neutralizing human monoclonal antibodies (mAbs) in SARS-CoV-2-infected animals. Whereas Fc effector functions are dispensable when representative neutralizing mAbs are administered as prophylaxis, they are required for optimal protection as therapy. When given after infection, intact mAbs reduce SARS-CoV-2 burden and lung disease in mice and hamsters better than loss-of-function Fc variant mAbs. Fc engagement of neutralizing antibodies mitigates inflammation and improves respiratory mechanics, and transcriptional profiling suggests these phenotypes are associated with diminished innate immune signaling and preserved tissue repair. Immune cell depletions establish that neutralizing mAbs require monocytes and CD8+ T cells for optimal clinical and virological benefit. Thus, potently neutralizing mAbs utilize Fc effector functions during therapy to mitigate lung infection and disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2021.02.026

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
<tt>edgeR</tt> : a Bioconductor package for differential expression analysis of digital gene expression data
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Merad, M., & Martin, J. C. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0331-4 · Cited by 2,472
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Self-citation
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853

Flagged first, then by citations

Show all 101 references

1 of the 101 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 370

Comparative transcriptomic analysis of SARS-CoV-2 infected cell model systems reveals differential innate immune responses
Sun, G., Cui, Q., Garcia, G., Wang, C., Zhang, M., Arumugaswami, V., Riggs, A. D., & Shi, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-96462-w · Cited by 44
Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals
Klingler, J., Lambert, G. S., Itri, V., Liu, S. T. H., Bandrés, J. C., Enyindah-Asonye, G. M., Liu, X., Simon, V. R., Gleason, C., Kleiner, G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.759688 · Cited by 44
Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
Pierre, C. N., Adams, L. E., Higgins, J. S., Anasti, K. M., Goodman, D. D., Mielke, D., Stanfield-Oakley, S., Powers, J. M., Li, D., Rountree, W., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011569 · Cited by 41
Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
Chitsike, L., & Duerksen-Hughes, P. J. (2021) · Virology Journal · doi:10.1186/s12985-021-01624-x · Cited by 45
Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants
Wu, W.-L., Chiang, C.-Y., Lai, S.-C., Yu, C.-Y., Huang, Y., Liao, H., Liao, C., Chen, H., & Liu, S. (2022) · JCI Insight · doi:10.1172/jci.insight.157597 · Cited by 41
Self-citation
Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response
Marconato, M., Abela, I. A., Hauser, A., Schwarzmüller, M., Katzensteiner, R., Braun, D. L., Epp, S., Audigé, A., Weber, J., Rusert, P., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158190 · Cited by 45
Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys
Fenwick, C. W., Turelli, P., Ni, D., Perez, L. H., Lau, K., Hérate, C., Marlin, R., Lana, E., Pellaton, C., Raclot, C., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01198-6 · Cited by 39
Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity
Chen, W., Hajduczki, A., Martinez, E. J., Bai, H., Matz, H. C., Hill, T. M., Lewitus, É., Chang, W. C., Dawit, L., Peterson, C. E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36106-x · Cited by 39
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
Strohl, W. R., Ku, Z., An, Z., Carroll, S. F., Keyt, B. A., & Strohl, L. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00529-7 · Cited by 35
Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects
Huynh, A., Arnold, D. M., Smith, J. W., Moore, J. C., Zhang, A., Chagla, Z., Harvey, B. J., Stacey, H. D., Ang, J. C., Clare, R., et al. (2021) · Viruses · doi:10.3390/v13040697 · Cited by 38
Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections
Keeler, S. P., & Fox, J. M. (2021) · Viruses · doi:10.3390/v13061037 · Cited by 38
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers
Schmidt, P., Narayan, K. M., Li, Y., Kaku, C. I., Brown, M. E., Champney, E. R., Geoghegan, J. C., Vásquez, M., Krauland, E. M., Yockachonis, T. J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg2783 · Cited by 35
Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters
Uraki, R., Kiso, M., Imai, M., Yamayoshi, S., Ito, M., Fujisaki, S., Takashita, E., Ujie, M., Furusawa, Y., Yasuhara, A., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01170-4 · Cited by 38
Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variantPreprint
Edara, V. V., Norwood, C., Floyd, K. A., Lai, L., Davis-Gardner, M. E., Hudson, W. H., Mantus, G. E., Nyhoff, L. E., Adelman, M. W., Fineman, R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.20.432046 · Cited by 37
Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences
Aiello, A., Fard, S. N., & Goletti, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1244556 · Cited by 38
Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis
Carpenter, S. M., & Lu, L. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830482 · Cited by 38
BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age
Bates, T. A., Lu, P., Kang, Y. J., Schoen, D., Thornton, M. A., McBride, S. K., Park, C., Kim, D., Messer, W. B., Curlin, M. E., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111544 · Cited by 32
Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors
Chen, R. E., Gorman, M. J., Zhu, D. Y., Carreño, J. M., Yuan, D., VanBlargan, L. A., Burdess, S., Lauffenburger, D. A., Kim, W., Turner, J. S., et al. (2021) · Med · doi:10.1016/j.medj.2021.11.004 · Cited by 37
Self-citation
Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives
Quirós-Roldán, E., Amadasi, S., Zanella, I., Antoni, M. D., Storti, S., Tiecco, G., & Castelli, F. (2021) · Pharmaceuticals · doi:10.3390/ph14121272 · Cited by 36
Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus
Lee, J., Zepeda, S. K., Park, Y., Taylor, A. L., Quispe, J. D., Stewart, C., Leaf, E. M., Treichel, C., Corti, D., King, N. P., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.10.018 · Cited by 33
An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer
Suryadevara, N., Shiakolas, A. R., VanBlargan, L. A., Binshtein, E., Chen, R. E., Case, J. B., Kramer, K. J., Armstrong, E., Myers, L., Trivette, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159062 · Cited by 31
Self-citation
An approach for evaluating the effects of dietary fiber polysaccharides on the human gut microbiome and plasma proteome
Delannoy-Bruno, O., Desai, C., Castillo, J. J., Couture, G., Barve, R. A., Lombard, V., Henrissat, B., Cheng, J., Han, N., Hayashi, D. K., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2123411119 · Cited by 33
The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccinesPreprint
Liu, Y., Arase, N., Kishikawa, J.-I., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., Ono, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.22.457114 · Cited by 31
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
Kapłonek, P., Cizmeci, D., Kwatra, G., Izu, A., Lee, J. S.-L., Bertera, H. L., Fischinger, S., Mann, C. J., Amanat, F., Wang, W., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01513-1 · Cited by 30
Protective non-neutralizing SARS-CoV-2 monoclonal antibodies
Izadi, A., & Nordenfelt, P. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.06.003 · Cited by 36
Repeated COVID-19 mRNA vaccination results in IgG4 class switching and decreased NK cell activation by S1-specific antibodies in older adults
Gelderloos, A. T., Verheul, M. K., Middelhof, I., de Zeeuw‐Brouwer, M., van Binnendijk, R. S., Buisman, A., & van Kasteren, P. B. (2024) · Immunity & Ageing · doi:10.1186/s12979-024-00466-9 · Cited by 31
Competing endogenous RNA network mediated by circ_3205 in SARS-CoV-2 infected cells
Barbagallo, D., Palermo, C. I., Barbagallo, C., Battaglia, R., Caponnetto, A., Spina, V., Ragusa, M., Pietro, C. D., Scalia, G., & Purrello, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04119-8 · Cited by 31
DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2
Parzych, E. M., Du, J., Ali, A., Schultheis, K., Frase, D. M., Smith, T. R. F., Cui, J., Chokkalingam, N., Tursi, N. J., Andrade, V. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33309-6 · Cited by 30
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections
Chow, M. Y. T., Pan, H. W., Seow, H. C., & Lam, J. K. W. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.11.006 · Cited by 32
Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines
Kapłonek, P., Deng, Y., Lee, J. S.-L., Zar, H. J., Zavadska, D., Johnson, M., Lauffenburger, D. A., Goldblatt, D., & Alter, G. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101048 · Cited by 32
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection
Garrett, M. E., Galloway, J. G., Wolf, C., Logue, J. K., Franko, N., Chu, H. Y., Matsen, F. A., IV, & Overbaugh, J. (2022) · eLife · doi:10.7554/elife.73490 · Cited by 32
The loss of OPA1 accelerates intervertebral disc degeneration and osteoarthritis in aged mice
Madhu, V., Hernandez-Meadows, M., Coleman, A., Sao, K., Inguito, K. L., Haslam, O., Boneski, P. K., Sesaki, H., Barve, R. A., Collins, J. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60933-9 · Cited by 38
Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features
Rowntree, L. C., Chua, B. Y. L., Nicholson, S. R., Koutsakos, M., Hensen, L., Douros, C., Selva, K. J., Mordant, F. L., Wong, C. Y., Habel, J. R., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1258 · Cited by 29
Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge
Nkumama, I. N., Ogwang, R., Odera, D., Musasia, F. K., Mwai, K., Nyamako, L., Murungi, L., Tuju, J., Fürle, K., Rosenkranz, M., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.05.001 · Cited by 32
Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection
Gunn, B. M., & Bai, S. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1976580 · Cited by 28
Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants
Liu, Z., Wu, H., Egland, K. A., Gilliland, T. C., Dunn, M. D., Luke, T. C., Sullivan, E. J., Klimstra, W. B., Bausch, C. L., & Whelan, S. P. J. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1940652 · Cited by 26
Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response
Marconato, M., Abela, I. A., Hauser, A., Schwarzmüller, M., Katzensteiner, R., Braun, D. L., Epp, S., Audigé, A., Weber, J., Rusert, P., et al. (2022) · PubMed Central · doi:10.5167/uzh-221980 · Cited by 27
Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo
Torchia, J. A., Tavares, A. H., Carstensen, L. S., Chen, D. W., Huang, J., Xiao, T., Mukherjee, S., Reeves, P. M., Tu, H., Sluder, A. E., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq6527 · Cited by 25
Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2
Grant, M. D., Bentley, K., Fielding, C. A., Hatfield, K. M., Ings, D. P., Harnum, D. O. A., Wang, E. C. Y., Stanton, R. J., & Holder, K. A. (2023) · JCI Insight · doi:10.1172/jci.insight.170681 · Cited by 29
Subclass-switched anti-spike IgG3 oligoclonal cocktails strongly enhance Fc-mediated opsonization
Izadi, A., Hailu, A., Godzwon, M., Wrighton, S., Olofsson, B., Schmidt, T., Söderlund‐Strand, A., Elder, E., Appelberg, S., Valsjö, M., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2217590120 · Cited by 28
Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodiesPreprint
Lempp, F., Soriaga, L. B., Montiel-Ruiz, M., Benigni, F., Noack, J., Park, Y.-J., Bianchi, S., Walls, A., Bowen, J., Zhou, J.-Y., et al. (2021) · bioRxiv · doi:10.1101/2021.04.03.438258 · Cited by 22
Fc‐ FcγR interactions during infections: From neutralizing antibodies to antibody‐dependent enhancement
Edgar, J. E., & Bournazos, S. (2024) · Immunological Reviews · doi:10.1111/imr.13393 · Cited by 32
Antibody-mediated immunity to SARS-CoV-2 spike
Errico, J. M., Adams, L. J., & Fremont, D. H. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.07.001 · Cited by 22
Single-dose HPV vaccine immunity: is there a role for non-neutralizing antibodies?
Quang, C., Chung, A. W., Frazer, I. H., Toh, Z. Q., & Licciardi, P. V. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.07.011 · Cited by 27
Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients
Rovito, R., Bono, V., Augello, M., Tincati, C., Mainoldi, F., Beaudoin-Bussières, G., Tauzin, A., Bianchi, S., Hadla, M., Yellenki, V., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-23923-1 · Cited by 25
Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
Struble, E. B., Rawson, J. M. O., Stantchev, T. S., Scott, D., & Shapiro, M. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051538 · Cited by 27
Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review
Cheng, Z. J., Xue, M., Zheng, P., Lyu, J., Zhan, Z., Hu, H., Zhang, Y., Zhang, X. D., & Sun, B. (2021) · Vaccines · doi:10.3390/vaccines9080869 · Cited by 26
Ibuprofen, other NSAIDs and COVID-19: a narrative review
Laughey, W., Lodhi, I., Pennick, G., Smart, L. J., Sanni, O., Sandhu, S., & Charlesworth, B. (2023) · InflammoPharmacology · doi:10.1007/s10787-023-01309-7 · Cited by 25
Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies
Stefan, M. A., Light, Y. K., Schwedler, J. L., McIlroy, P. R., Courtney, C. M., Saada, E. A., Thatcher, C. E., Phillips, A. M., Bourguet, F. A., Mageeney, C. M., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1958663 · Cited by 25
Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo
Edgar, J. E., Trezise, S., Anthony, R. M., Krammer, F., Palese, P., Ravetch, J. V., & Bournazos, S. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314905120 · Cited by 24
Loss of function mutation in Ank causes aberrant mineralization and acquisition of osteoblast-like-phenotype by the cells of the intervertebral disc
Ohnishi, T., Tran, V., Sao, K., Ramteke, P. L., Querido, W., Barve, R. A., van de Wetering, K., & Risbud, M. V. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05893-y · Cited by 18
Structural basis for broad sarbecovirus neutralization by a human monoclonal antibodyPreprint
Tortorici, M. A., Czudnochowski, N., Starr, T. N., Marzi, R., Walls, A. C., Zatta, F., Bowen, J. E., Jaconi, S., di Iulio, J., Wang, Z., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.07.438818 · Cited by 22
Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escapePreprint
Starr, T. N., Czudnochowski, N., Zatta, F., Park, Y., Liu, Z., Addetia, A., Pinto, D., Beltramello, M., Hernandez, P., Greaney, A. J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.06.438709 · Cited by 24
In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies
Pagant, S., & Liberatore, R. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111882 · Cited by 21
SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy
Singh, D. D., Sharma, A., Lee, H., & Yadav, D. K. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.839170 · Cited by 23
Dynamic response antibodies SARS-CoV-2 human saliva studied using two-dimensional correlation (2DCOS) infrared spectral analysis coupled with receiver operation characteristics analysis
Karthikeyan, S., Mata-Miranda, M. M., Martínez-Cuazitl, A., Delgado-Macuil, R. J., Garibay-Gonzalez, F., Monroy, V. S., López-Reyes, A. G., Rojas‐López, M., Rivera-Alatorre, D. E., & Vázquez-Zapién, G. J. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166799 · Cited by 20
A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques
Cobb, R. R., Nkolola, J. P., Gilchuk, P., Chandrashekar, A., Yu, J., House, R. V., Earnhart, C. G., Dorsey, N. M., Hopkins, S. A., Snow, D. M., et al. (2022) · Med · doi:10.1016/j.medj.2022.01.004 · Cited by 20
Self-citation
Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19
Li, D., Hu, J., Li, D., Yang, W., Yin, S., & Qiu, R. (2021) · Topics in Current Chemistry · doi:10.1007/s41061-020-00318-2 · Cited by 18
A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection
Adams, L. J., VanBlargan, L. A., Liu, Z., Gilchuk, P., Zhao, H., Chen, R. E., Raju, S., Chong, Z., Whitener, B. M., Shrihari, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101305 · Cited by 18
Self-citation
The dual role of IgG4 in immunity: bridging pathophysiology and therapeutic applications
Piseddu, I., Mayerle, J. V., Mahajan, U. M., & Boehmer, D. F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335375 · Cited by 22
The Role of Innate Immunity and Bioactive Lipid Mediators in COVID-19 and Influenza
Sahanic, S., Löffler‐Ragg, J., Tymoszuk, P., Hilbe, R., Demetz, E., Masanetz, R. K., Theurl, M., Holfeld, J., Gollmann‐Tepeköylü, C., Tzankov, A., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.688946 · Cited by 18
Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters
Su, W., Sia, S. F., Schmitz, A. J., Bricker, T. L., Starr, T. N., Greaney, A. J., Turner, J. S., Mohammed, B. M., Liu, Z., Choy, K. T., et al. (2021) · mBio · doi:10.1128/mbio.02395-21 · Cited by 17
Self-citation
SARS-CoV-2 Spike Expression at the Surface of Infected Primary Human Airway Epithelial Cells
Ding, S., Adam, D., Beaudoin-Bussières, G., Tauzin, A., Gong, S. Y., Gasser, R., Laumaea, A., Anand, S. P., Privé, A., Bourassa, C., et al. (2021) · Viruses · doi:10.3390/v14010005 · Cited by 18
Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern
Kováčech, B., Fialová, Ľ., Filipčík, P., Škrabana, R., Žilková, M., Ivanovova, N. P., Kováč, A., Palova, D., Rolkova, G., Tomkova, K., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103818 · Cited by 19
Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates
Zhu, D. Y., Gorman, M. J., Yuan, D., Yu, J., Mercado, N. B., McMahan, K., Borducchi, E. N., Lifton, M. A., Liu, J., Nampanya, F., et al. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001609 · Cited by 18
Self-citation
Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants
Haycroft, E. R., Davis, S. K., Ramanathan, P., López, E., Purcell, R. A., Tan, L. L., Pymm, P., Wines, B. D., Hogarth, P. M., Wheatley, A. K., et al. (2023) · Medical Microbiology and Immunology · doi:10.1007/s00430-023-00773-w · Cited by 21
Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain
Sankhala, R. S., Dussupt, V., Chen, W., Bai, H., Martinez, E. J., Jensen, J. L., Rees, P. A., Hajduczki, A., Chang, W. C., Choe, M., et al. (2023) · Structure · doi:10.1016/j.str.2023.11.015 · Cited by 17
Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants
Banerjee, A., Lew, J. M., Kroeker, A., Baid, K., Aftanas, P., Nirmalarajah, K., Maguire, F., Kozak, R. A., McDonald, R. R., Lang, A. L. S., et al. (2022) · Med · doi:10.1016/j.medj.2022.04.002 · Cited by 18
Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant
Richardson, S. I., Kgagudi, P., Manamela, N. P., Kaldine, H., Venter, E. M., Pillay, T., Lambson, B. E., van der Mescht, M. A., Hermanus, T., Balla, S. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100910 · Cited by 18
Distinct gene expression signatures comparing latent tuberculosis infection with different routes of Bacillus Calmette-Guérin vaccination
Silver, R. F., Xia, M., Storer, C. E., Jarvela, J. R., Moyer, M., Blazevic, A., Stoeckel, D. A., Rakey, E. K., Tennant, J. M., Goll, J. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44136-8 · Cited by 17
Self-citation
Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV
Chao, C. W., Sprouse, K. R., Miranda, M. C., Catanzaro, N., Hubbard, M. L., Addetia, A., Stewart, C., Brown, J. T., Dosey, A. M., Valdez, A., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115036 · Cited by 18
Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation
van der Straten, K., van Gils, M. J., de Taeye, S. W., & de Bree, G. J. (2022) · Frontiers in Medical Technology · doi:10.3389/fmedt.2022.867982 · Cited by 17
Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein
Hong, Y., Guo, H., Wei, M., Zhang, Y., Fang, M., Cheng, T., Li, Z., Ge, S., Yao, X., Yuan, Q., et al. (2022) · Journal of Virological Methods · doi:10.1016/j.jviromet.2022.114564 · Cited by 16
Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection
Wieczorek, L., Zemil, M., Merbah, M., Dussupt, V., Kavusak, E., Molnar, S., Heller, J., Beckman, B., Wollen-Roberts, S. E., Peachman, K. K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901217 · Cited by 16
The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose
Mazarakis, N., Toh, Z. Q., Neal, E. F. G., Bright, K., Luu, S., Quah, L., Ng, Y. Y., Nguyen, C. D., Hart, J., Do, L. A. H., et al. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106447 · Cited by 16
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
Wines, B. D., Kurtovic, L., Trist, H. M., Esparon, S. E., López, E., Chappin, K., Chan, L., Mordant, F. L., Lee, W. S., Gherardin, N. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.889372 · Cited by 15
Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination
Motsoeneng, B. M., Manamela, N. P., Kaldine, H., Kgagudi, P., Hermanus, T., Ayres, F., Makhado, Z., Moyo-Gwete, T., van der Mescht, M. A., Abdullah, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1231276 · Cited by 14
Diverging Maternal and Cord Antibody Functions From SARS-CoV-2 Infection and Vaccination in Pregnancy
Adhikari, E. H., Lu, P., Kang, Y. J., McDonald, A. R., Pruszynski, J. E., Bates, T. A., McBride, S. K., Trank-Greene, M., Tafesse, F., & Lu, L. L. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad421 · Cited by 15
Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization
Yang, J., Lin, S., Chen, Z., Yang, F., Guo, L., Wang, L., Duan, Y., Zhang, X., Dai, Y., Yin, K., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011804 · Cited by 16
Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques
Sankhala, R. S., Lal, K. G., Jensen, J. L., Dussupt, V., Mendez-Rivera, L., Bai, H., Wieczorek, L., Mayer, S. V., Zemil, M., Wagner, D. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44265-0 · Cited by 15
A novel plant‐made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS‐CoV ‐2 Omicron variant
Jugler, C., Sun, H., Nguyen, K., Palt, R., Felder, M., Steinkellner, H., & Chen, Q. (2022) · Plant Biotechnology Journal · doi:10.1111/pbi.13970 · Cited by 16
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutationsPreprint
Bertoglio, F., Fühner, V., Ruschig, M., Heine, P. A., Abasi, L., Klünemann, T., Rand, U., Meier, D., Langreder, N., Steinke, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.03.409318 · Cited by 18
Vaccinal effect of HIV-1 antibody therapy: dream or reality?
Naranjo‐Gómez, M., & Pelegrín, M. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000797 · Cited by 15
A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo
Aschner, C. B., Muthuraman, K., Kucharska, I., Cui, H., Prieto, K., Nair, M. S., Wang, M., Huang, Y., Christie-Holmes, N., Poon, B., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf4549 · Cited by 15
Self-citation
Deciphering Fc-effector functions against SARS-CoV-2
Beaudoin-Bussières, G., & Finzi, A. (2024) · Trends in Microbiology · doi:10.1016/j.tim.2024.01.005 · Cited by 19
Antibody‐mediated control mechanisms of viral infections
Mackin, S., Sariol, A., & Diamond, M. (2024) · Immunological Reviews · doi:10.1111/imr.13383 · Cited by 15
Self-citation
NSAIDs and Kelleni’s protocol as potential early COVID-19 treatment game changer: could it be the final countdown?
Kelleni, M. T. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00896-7 · Cited by 15
Neutralizing and enhancing antibodies against SARS-CoV-2
Liu, Y., & Arase, H. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00233-7 · Cited by 13
A Recent SARS-CoV-2 Infection Enhances Antibody-Dependent Cellular Cytotoxicity against Several Omicron Subvariants following a Fourth mRNA Vaccine Dose
Beaudoin-Bussières, G., Tauzin, A., Dionne, K., Gendron‐Lepage, G., Medjahed, H., Perreault, J., Levade, I., Alfadhli, L., Bo, Y., Bazin, R., et al. (2023) · Viruses · doi:10.3390/v15061274 · Cited by 15
Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations
Purcell, R. A., Theisen, R. M., Arnold, K. B., Chung, A. W., & Selva, K. J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183727 · Cited by 16
SARS-CoV-2 infection prior to vaccination amplifies Fc-mediated humoral profiles in an age-dependent manner
Jung, W., Abdelnour, A., Kapłonek, P., Herrero, R., Lee, J. S.-L., Barbati, D. R., Chicz, T. M., Levine, K. S., Fantin, R., Loría, V., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114684 · Cited by 13
Heterologous SARS‐CoV ‐2 IgA neutralising antibody responses in convalescent plasma
Davis, S. K., Selva, K. J., López, E., Haycroft, E. R., Lee, W. S., Wheatley, A. K., Juno, J. A., Adair, A., Pymm, P., Redmond, S. J., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1424 · Cited by 14
Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2
Burnouf, T., Gathof, B. S., Bloch, E. M., Bazin, R., Angelis, V. D., Patidar, G. K., Rastvorceva, R. M. G., Oreh, A. C., Goel, R., Rahimi‐Levene, N., et al. (2022) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2022.06.001 · Cited by 13
Assessment of serological assays for identifying high titer convalescent plasma
Farnsworth, C. W., Case, J. B., Hock, K. G., Chen, R. E., O’Halloran, J. A., Presti, R. M., Goss, C. W., Rauseo, A. M., Ellebedy, A. H., Theel, E. S., et al. (2021) · Transfusion · doi:10.1111/trf.16580 · Cited by 13
Self-citation
Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profilesPreprint
Kapłonek, P., Cizmeci, D., Fischinger, S., Collier, A.-R. Y., Suscovich, T. J., Linde, C., Broge, T. A., Mann, C. J., Amanat, F., Dayal, D., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.31.458247 · Cited by 13
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 11
Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model
Imbrechts, M., Maes, W., Ampofo, L., den Berghe, N. V., Calcoen, B., Looveren, D. V., Kerstens, W., Rasulova, M., Vercruysse, T., Noppen, S., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104705 · Cited by 13
Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans
Xu, S., Carpenter, M. C., Spreng, R. L., Neidich, S. D., Sarkar, S., Tenney, D., Goodman, D. D., Sawant, S. S., Jha, S., Dunn, B., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00514-9 · Cited by 12
SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations
Hederman, A. P., Natarajan, H., Heyndríckx, L., Ariën, K. K., Wiener, J. A., Wright, P. F., Bloch, E. M., Tobian, A. A. R., Redd, A. D., Blankson, J. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40960-0 · Cited by 19
Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies
Inoue, T., Yamamoto, Y., Sato, K., Okemoto‐Nakamura, Y., Shimizu, Y., Ogawa, M., Onodera, T., Takahashi, Y., Wakita, T., Kaneko, M. K., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109363 · Cited by 12

Authors: Winkler, E. S., Gilchuk, P., Yu, J., Bailey, A. L., Chen, R. E., Chong, Z., Zost, S. J., Jang, H., Huang, Y., Allen, J. D., Case, J. B., Sutton, R. E., Carnahan, R. H., Darling, T. L., Boon, A. C. M., Mack, M., Head, R. D., Ross, T. M., Crowe, J. E., & Diamond, M. S.
Affiliations: Washington University in St. Louis (US)
Vanderbilt University Medical Center (US)
University of Georgia (US)
University Hospital Regensburg (DE)
Corresponding author: Crowe, James E.
Diamond, Michael S.
ORCID: Winkler, Emma S.
Gilchuk, Pavlo
Yu, Jinsheng
Bailey, Adam L.
Chen, Rita E.
Chong, Zhenlu
Zost, Seth J.
Jang, Hyesun
Huang, Ying
Allen, James D.
Case, James Brett
Carnahan, Robert H.
Darling, Tamarand L.
Boon, Adrianus C.M.
Mack, Matthias
Head, Richard D.
Ross, Ted M.
Crowe, James E.
Diamond, Michael S.
Venue: Cell
Publisher: Elsevier BV
Published: 2021-04
Volume: 184
Issue: 7
Pages: 1804-1820.e16
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2021.02.026
PMC: PMC7879018
OpenAlex: W3132982761
Cited by: 366
References: 101
Citations by year: 2026: 13 · 2025: 34 · 2024: 40 · 2023: 69 · 2022: 99 · 2021: 109
FWCI: 25.26
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Cell (publishedVersion)
bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
PubMed Central (submittedVersion)
University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
Funders: NIAID
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords: SARS-CoV-2, neutralizing monoclonal antibodies, Fc effector functions, passive immunotherapy, COVID-19 pandemic, pulmonary infection, monocytes, CD8+ T cells, innate immune signaling, tissue repair, inflammation, correlates of protection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks